Usted buscó: kardiovaskularno (Esloveno - Inglés)

kardiovaskularno
cardiovascular

kardiovaskularno popuščanje
cardiovascular inability

kardiovaskularno ocenjevanje:
cardiovascular evaluation:

za kardiovaskularno uporabo
for cardiovascular use

učinki na presnovo lipidov in kardiovaskularno tveganje:
effects on lipid metabolism and cardiovascular risk:

indikacija za kardiovaskularno preventivo je utemeljena z rezultati študije hope.
the indication for cardiovascular prevention is justified by the results of hope study.

učinka zdravila lojuxta na kardiovaskularno obolevnosti in umrljivosti niso ugotovili.
the effect of lojuxta on cardiovascular morbidity and mortality has not been determined.

vpliv zdravila praluent na kardiovaskularno obolevnost in umrljivost še ni ugotovljen.
the effect of praluent on cardiovascular morbidity and mortality has not yet been determined.

vplivi zdravila rasilez na umrljivost in kardiovaskularno obolevnost trenutno niso znani.
effects of rasilez on mortality and cardiovascular morbidity are currently unknown.

v primeru izrazite hipotenzije bo morda treba uvesti aktivno kardiovaskularno podporo.
in the case of pronounced hypotension, active cardiovascular support may be required.

ne uporabljajte pri psih s hudo jetrno okvaro, hudo ledvično ali hudo kardiovaskularno boleznijo.
do not use in dogs with severely impaired hepatic function, severe renal or severe cardiovascular disorders.

pljučni vazodilatatorji lahko močno poslabšajo kardiovaskularno stanje bolnikov s pljučno venookluzivno boleznijo.
pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease.

okvara srca je bila opredeljena kot stanje bolnikov, ki so predhodno imeli neko kardiovaskularno nepravilnost.
cardiac impairment was defined as patients with previous cardiovascular abnormality.

Če pride do prevelikega odmerjanja, je treba uvesti ustrezno respiratorno in kardiovaskularno podporno zdravljenje.
should overdosage occur, the respiratory and cardiovascular systems should be supported appropriately.

ugodni vplivi zdravila riprazo na umrljivost, kardiovaskularno obolevnost in prizadetost tarčnih organov trenutno niso znani.
beneficial effects of riprazo on mortality and cardiovascular morbidity and target organ damage are currently unknown.

kardiovaskularno depresijo je treba zdraviti z ekspanderji plazme, presornimi sredstvi, antiaritmičnimi sredstvi ali drugimi ustreznimi metodami.
cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.

kot pri vseh antihipertenzivih lahko preveliko znižanje krvnega tlaka pri bolnikih z ishemično kardiopatijo ali ishemično kardiovaskularno boleznijo povzroči miokardni infarkt ali kap.
as with any anti-hypertensive agent, excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular disease could result in a myocardial infarction or stroke.

posebno pozornost je treba nameniti sladkornim bolnikom, ki imajo sočasno bolezen koronarnih arterij, hipertenzijo ali kardiovaskularno avtonomno nevropatijo.
particular attention should be given to diabetic patients with comorbidities of coronary artery disease, hypertension and cardiovascular autonomic neuropathy.

omejene klinične izkušnje z uporabo sevoflurana pri psih z ledvično, jetrno in kardiovaskularno insuficienco kažejo, da lahko sevofluran pri teh boleznih varno uporabljamo.
limited clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions.

ne uporabljajte pri psih s hudo jetrno okvaro, hudo ledvično ali hudo kardiovaskularno boleznijo (glejte poglavje 4.7.).
do not use in dogs with severely impaired hepatic function, severe renal or severe cardiovascular disorders (see section 4.7).